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PRL gene expression is dependent on the pres-
ence of the pituitary-specific transcription factor
GHF-1/Pit-1, which is transcribed in a highly re-
stricted manner in cells of the anterior pituitary. In
pituitary GH3 cells, vitamin D increases the levels
of PRL transcripts and stimulates the PRL pro-
moter. We have analyzed the role of GHF-1 and of
the vitamin D receptor (VDR) to confer vitamin D
responsiveness to the PRL promoter. For this pur-
pose we have used nonpituitary HeLa cells, which
do not express GHF-1. We found that VDR acti-
vates the PRL promoter both in a ligand-dependent
and -independent manner through a sequence lo-
cated between positions 245/227 in the proximal
5*-flanking region. This sequence also confers VDR
and vitamin D responsiveness to a heterologous
promoter. In the context of the PRL gene, VDR
requires the presence of GHF-1 to activate the pro-
moter. Truncation of the last 12 C-terminal amino
acids of VDR, which contain the ligand-dependent
activation function (AF2), abolishes regulation by
vitamin D, suggesting that binding of coactivators
to this region mediates ligand-dependent stimula-
tion of the PRL promoter by the receptor. Indeed,
expression of the coactivators, steroid hormone
receptor coactivator-1 (SRC-1) and CREB-binding
protein (CBP), significantly enhances the stimula-
tory effect of vitamin D mediated by the wild-type
VDR but not by the AF2 mutant receptor. Further-
more, CBP also increases the activation of the PRL
promoter by GHF-1 and the ligand-independent ac-
tivation by both wild-type and mutant VDR. (Mo-
lecular Endocrinology 13: 1141–1154, 1999)
INTRODUCTION
Tissue-specific and developmental expression of eu-
karyotic genes is typically governed by combinations
of cell type-specific and ubiquitous transcription fac-
tors (1). GHF-1/Pit-1 is a pituitary-specific POU-
Homeobox transcription factor that regulates GH,
PRL, and TSHb gene expression through binding to
specific promoter sequences (2–4). The 59-flanking re-
gion of the PRL gene contains several GHF-1 binding
sites clustered in two domains: a distal enhancer
(21800 to 21500 bp), and a proximal promoter (2422
to 133 bp) both containing four GHF-1 binding sites
(5). Multiple hormones, growth factors, and onco-
genes act in conjunction with GHF-1 to regulate the
expression of the PRL gene. The DNA elements as well
as the transcription factors responsible for the regu-
lation by some of these stimuli have been identified.
Thus, different ligands of tyrosine kinase receptors, as
well as the src, ras, and raf oncogenes, activate PRL
gene expression, and the downstream effector for
these stimuli appear to be the ubiquitous Ets factors,
which bind to the proximal PRL promoter (6, 7). The
proximal promoter region also contains a basal tran-
scription element (BTE) as well as sequences confer-
ring cAMP responsiveness [cAMP-response element
(CRE)] to the PRL gene. An estrogen response element
(ERE) located in the distal enhancer binds estrogen
receptors and confers estradiol responsiveness to the
PRL gene (8). Other ligands of nuclear receptors have
also been described to regulate PRL gene transcrip-
tion both positively and negatively (9).
1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] (vitamin
D), the active form of vitamin D3, exerts its biological
activities through binding to a specific receptor [vita-
min D receptor (VDR)], a member of the nuclear hor-
mone receptor superfamily, which also includes retin-
oid, thyroid hormone, and steroid hormone receptors
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(10), and it displays a modular structure with several
regions (A/B, C, D, and E). Transcriptional regulation
by nuclear receptors is achieved through autonomous
activation functions (AFs): a constitutive N-terminal
AF1 contained in the A/B region, and a ligand-depen-
dent AF2 located in the C-terminal E region of the
ligand-binding domain (LBD). The E region also con-
tains a dimerization interface. The highly conserved C
domain contains two zinc fingers responsible for DNA
binding and sequence-specific recognition. VDR, as a
homodimer or preferentially as a heterodimer with the
retinoid X receptor (RXR), binds to vitamin D-respon-
sive elements (VDREs) in promoters of vitamin D target
genes and modulates their transcription. In most
cases, the VDREs consist of DR-3 elements (direct
repeats of the consensus hexanucleotide motif (A/G)
(A/G)(G/T)N(C/G)A separated by 3 bp) (11).
In the past few years the mechanism of transcrip-
tional activation by nuclear receptors has been further
elucidated by the discovery of a new class of proteins
known as transcriptional coactivators. Some coacti-
vators, such as the two related proteins CREB (CRE-
binding protein)-binding protein (CBP) and p300, me-
diate the effects of diverse groups of transcription
factors (12, 13), whereas other coactivators are more
specific for the nuclear receptors. This class of spe-
cific factors include, among others, the steroid hor-
mone receptor coactivator-1 (SRC-1/NCoA1) (14, 15).
Recent crystallographic studies (15) have shown that
ligand binding induces a structural change in the AF2
region, which allows the recruitment of coactivators
and enhances ligand-induced transactivation.
GH- and PRL-secreting pituitary tumor cells (GH
cells), which possess specific receptor sites for vita-
min D (16), have previously been found to respond to
this ligand with a selective increase in PRL synthesis
and secretion, without affecting GH (17). This induc-
tion is secondary to stimulation of PRL gene expres-
sion, but the promoter elements responsible for this
effect have not yet been identified.
In this report, we have analyzed the effect of vitamin
D on PRL gene expression in pituitary GH3 cells, as
well as the contribution of GHF-1 and VDR to the
stimulation of the PRL promoter by vitamin D. To avoid
the problem of endogenous expression of GHF-1 and
receptors in pituitary cell lines, we have performed
transient cotransfection assays with GHF-1 and wild-
type and mutant receptors in a heterologous cell sys-
tem (HeLa cells). We found that VDR activates the PRL
promoter both in a ligand-dependent and a ligand-
independent manner through a VDRE located in the
proximal promoter region, and that this activation re-
quires the presence of GHF-1. A VDR mutant lacking
the AF2 region exhibits full constitutive activity, but
does not confer ligand-dependent transactivation. In-
deed, expression of the coactivator SRC-1 and CBP
dramatically potentiates the vitamin D response me-
diated by the wild-type VDR, but not by the mutant
receptor. However, both coactivators have differential
effects: CBP (but not SRC-1) increases the constitu-
tive vitamin D-independent activation of the promoter
by truncated and wild-type VDR. Since CBP also
strongly stimulates the response to GHF-1 in the ab-
sence of receptors, these results suggest a broader
role for this cointegrator in PRL gene expression.
RESULTS
Vitamin D Increases PRL Transcripts and
Stimulates PRL Promoter Activity in Pituitary
GH3 Cells
As shown in Fig. 1A, incubation of GH3 cells with 100
nM vitamin D for 48 h caused a significant increase of
PRL mRNA levels. Quantification of Northern blots
from three independent experiments showed that this
concentration of vitamin D increased PRL transcripts
in GH3 cells by 3.3 6 0.2 fold. To study whether
sequences contained within the 59-flanking region of
the PRL gene mediate induction by vitamin D in these
cells, the construct 23000PRLCAT was used in tran-
sient transfection assays. Since transcriptional effect
of different nuclear receptors can be interfered by
AP-1 factors, this construct lacks the AP-1 binding
motif present in the plasmid backbone (19). As illus-
trated in Fig. 1B, vitamin D caused an approximately
3-fold increase in chloramphenicol acetyltransferase
(CAT) activity, a value similar to that found for the
increase in endogenous PRL transcripts. In contrast
with the results obtained in GH3 cells, we were unable
to find stimulation of the PRL gene by vitamin D in
GH4C1 cells, another rat pituitary cell line (data not
shown).
Vitamin D Activates the PRL Promoter in
Nonpituitary HeLa Cells
Consistent with the physiological role for vitamin D in
the regulation of PRL gene expression in rat pituitary
cells (17), we decided to analyze the role of VDR on
PRL gene activation by vitamin D, as well as the par-
ticipation of GHF-1 in this response. For this purpose
we used the nonpituitary HeLa cell line, which is de-
rived from a human cervical carcinoma and does not
express endogenous PRL or the pituitary-specific fac-
tor GHF-1 (18). To characterize the interaction be-
tween GHF-1 and VDR on PRL gene activation by
vitamin D, the reporter plasmid 23000PRLCAT was
cotransfected with VDR in the presence or absence of
a GHF-1 expression vector. As shown in Fig. 2, basal
CAT activity was very low in HeLa cells in the absence
of GHF-1 and was not affected by vitamin D. Further-
more, this activity was not modified by expression of
VDR alone, either in the presence or in the absence of
the ligand. However, after expression of GHF-1, which
by itself had little stimulatory effect, a strong synergis-
tic response was observed and vitamin D caused a
marked promoter stimulation. As can also be ob-
served in Fig. 2, unliganded VDR was able to cooper-
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ate with GHF-1 to cause a significant increase of CAT
activity, although this constitutive activity was mark-
edly enhanced upon incubation with the ligand. In
contrast, vitamin D did not activate the PRL construct
in the absence of transfected VDR, even when GHF-1
was present, showing that endogenous VDR levels are
not sufficient to stimulate the PRL promoter in HeLa
cells. The same PRL promoter fragment (23000 to
174) containing the AP-1 site in the plasmid backbone
showed a stronger response to GHF-1, but the re-
sponses to VDR and vitamin D3 were not affected
(data not shown).
5*-Flanking Sequences in the Proximal PRL
Promoter Confer Vitamin D Responsiveness
A series of 59-deletion constructs were used to deter-
mine the gene elements responsible for PRL promoter
stimulation by vitamin D. All constructs contained the
first 74 bp of the coding PRL region and lacked the AP-1
binding site. In contrast with the results obtained with the
23000PRLCAT plasmid, CAT levels were essentially un-
detectable in GH3 cells transfected with shorter pro-
moter fragments and, therefore, further mapping could
not be carried out in these cells (Fig. 3B). In contrast, CAT
activity was detectable in HeLa cells transfected with the
different deletions. Figure 3A shows that the 21597,
2425, and 2176 constructs exhibit similar ligand-de-
pendent activation upon cotransfection with expression
vectors for VDR and GHF-1. As with the 23000PRLCAT
plasmid, a weaker ligand-independent activation was
also observed. Deletion to 2101 bp significantly reduced
vitamin D response, although constitutive activation was
still observed, and both responses were totally lost in the
construct extending only to 276. This gradual loss of
response suggests either the existence of more than only
one VDRE (some of which could be located between
2176 and 2101), or that the VDRE cooperates with
other promoter sequences to confer full vitamin D
responsiveness.
Mapping of the Vitamin D Response Element
To identify the possible vitamin D3 response ele-
ment(s) in the proximal promoter of the PRL gene, gel
Fig. 1. Vitamin D Activates PRL Gene Expression in Pituitary GH3 Cells
A, Northern blot analysis were carried out with 20 mg of total RNA from duplicate cultures of control cells and cells treated for
48 h with 100 nM vitamin D. The blot was hybridized with a labeled cDNA probe for rat PRL. The lower panel shows the ribosomal
18S RNA. B, GH3 cells were transfected with 5 mg of the PRL promoter construct 23000 PRLCAT, and CAT activity was
determined after 48 h in untreated cultures and in cultures treated with 100 nM vitamin D. The data show the mean 6 SD values
obtained in a representative experiment performed with triplicate cultures.
Fig. 2. GHF-1 Cooperates with VDR to Stimulate the PRL
Promoter in HeLa Cells in a Vitamin D-Dependent and -Inde-
pendent Manner
The plasmid 23000 PRLCAT (5 mg) was cotransfected with
expression vectors for GHF-1 (0.4 mg) and/or VDR (2.5 mg).
After 48 h, CAT activity was determined in untreated cultures
and in cultures treated with 100 nM vitamin D (black bars). The
data show the mean 6 SD values obtained in a representative
experiment performed with triplicate cultures.
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mobility shift experiments were conducted with a la-
beled promoter fragment spanning from 2176 to 174
(which confers a full CAT response to vitamin D), a
2101 to 174 fragment (which shows a partial re-
sponse), and a 270 to 174 promoter fragment (which
is unresponsive to vitamin D in the transfection as-
says). The region from 2176 to 2101 was also used in
the assays. As depicted in Fig. 4A, the promoter region
between 2176 and 2101 contains two GHF-1 binding
sites, one of them included in the composite Ets-
GHF-1 binding site, which is required to mediate PRL
promoter activation by oncogenic ras [Ras-responsive
element (RRE)] (20). These elements could participate
in the response to vitamin D3. Truncation to 2101
deletes the RRE (2165/2150). The 276 to 174 frag-
ment, which is unresponsive to vitamin D, has lost an
additional Ets binding site, the CRE (2101/292), and
the BTE (298/285). Since VDR can function as a
homodimer or as a VDR/RXR heterodimer (21), we
analyzed the formation of these complexes on the
proximal promoter regions. As shown in Fig. 4B (left
panel), the fragment from 2176 to 174 formed a weak
complex with VDR (lane 3). RXR alone also bound
weakly to this fragment (lane 2), but caused the for-
mation of VDR/RXR heterodimers that bind strongly to
the promoter (lane 4), indicating a preference for het-
erodimeric binding to the response element. This het-
erodimeric complex was removed by antibodies
against both VDR (lane 5) and RXR (lane 6). Identical
results were obtained when the promoter region from
2101 to 174 was used in the mobility shift assays
(data not shown), demonstrating that the VDRE was
contained within this fragment. In contrast, as shown
in lanes 7–10, the region comprised between 2176
and 2101 did not bind the receptors although GHF-1
binding to this fragment was readily observed (not
illustrated). These results suggested that the VDRE
could be located between 2101 and 276 bp. How-
ever, as shown in lanes 11 and 12, although the 276
to 174 region is not sufficient to confer vitamin D
responsiveness to the PRL promoter in transient trans-
fection studies, these sequences still contain the
VDRE. Again, VDR binding was significantly enhanced
in the presence of its heterodimeric partner RXR,
showing the preference for binding of VDR/RXR het-
erodimers to this fragment (lane 12). These results
indicate that although the VDRE is located in this pro-
moter region, other upstream sequences are required
to confer responsiveness to vitamin D3. To further map
the VDRE, the 276 to 174 region was digested with
Pst-1 to generate two new fragments: 276 to 210 and
29 to 174 (Fig. 4A). Each region was end labeled with
32P and used in mobility shift experiments with VDR
and RXR. The formation of VDR/RXR complexes was
observed with the 276 to 210 fragment (lane 14), but
not with the 29 to 174 fragment (lane 16), demon-
strating that the VDRE is located between 276 and
210 bp in the promoter.
Since VDR actions on the PRL promoter depended
on the presence of GHF-1 and both transcription fac-
tors produced a synergistic effect, we explored the
possibility that binding of GHF-1 and VDR/RXR could
be cooperative. Figure 4B (right panel, lanes 1–10)
shows binding of VDR and VDR/RXR alone or in com-
bination with GHF-1 to the labeled 276 to 174 frag-
ment. This promoter region contains one GHF-1 bind-
Fig. 3. Proximal Promoter Sequences Mediate Stimulation by Vitamin D
A, HeLa cells were cotransfected with 5 mg of reporter CAT constructs containing progressive deletions of the PRL promoter
and expression vectors for GHF-1 (0.4 mg) and/or VDR (2.5 mg). The cells transfected with GHF-1 in addition to VDR were
incubated for 48 h in the presence or absence of 100 nM vitamin D (vit. D). The data represent the mean CAT activity of four
independent assays. B, GH3 cells were transfected with the constructs indicated and CAT activity was determined after 48 h
treatment in the presence and absence of vit. D as indicated. The data show the values obtained from three independent
transfections.
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ing site and the VDRE. The addition of GHF-1 to the
VDR or VDR/RXR binding reactions neither facilitated
the binding of the receptors nor resulted in the forma-
tion of new complexes different from those formed in
reactions containing each protein individually. Thus,
both factors can bind independently to the promoter
and do not show cooperative binding. The preference
for the formation of VDR/RXR complexes, rather than
VDR homodimers (21), suggests that the VDRE in the
PRL promoter could consist of a direct repeat (DR)
motif with a spacer of three nucleotides. This was
confirmed in competition reactions with an unlabeled
consensus DR-3 oligonucleotide. Binding of the VDR/
RXR complex was competed specifically by this oli-
gonucleotide (lanes 6 and 9), but not by a sequence
containing a GHF-1 binding site (lane 10). The latter
effectively competed binding of the GHF-1 complex
(lanes 3 and 10), which in turn was not affected by the
DR-3 oligonucleotide (lane 9). As also shown in Fig.
4B, binding of VDR/RXR to the PRL promoter fragment
occurs irrespectively of the presence of vitamin D
(lanes 5 and 8).
Since the data shown in Fig. 4B indicate that the
VDRE must be contained between the nucleotides
276 and 210 in the PRL promoter, we screened this
promoter region for consensus VDR-binding sites.
This sequence was compared with 18 known natural
VDREs (reviewed in Ref. 11). As illustrated in Fig. 5A,
three overlapping putative VDREs in the 245 to 214
region were found. Oligonucleotides designed to con-
tain all of them (A), the two most 59-motifs (B), or the
most 39-motifs (C) were assayed in a mobility shift
experiment. The A and B oligonucleotides bound VDR/
RXR heterodimers, although binding was slightly less
intense with the B sequence (lanes 4 and 8, respec-
tively). Furthermore, the receptors bound to the pro-
moter fragments and to these oligonucleotides with a
similar strength (compare Figs. 4B and 5C). In con-
trast, the C fragment bound VDR homodimers with a
similar low affinity to the A or B oligonucleotides (lane
11), but binding of VDR/RXR heterodimers was almost
undetectable (lane 12). These results suggest that the
B sequence, which contains the DR-3 motifs, is the
one responsible for PRL gene response to vitamin D.
Fig. 4. Binding of VDR/RXR Heterodimers to the Region between Positions 276 and 210 of the PRL Promoter
A, Schematic representation of the proximal PRL promoter from nucleotides 2176 to 174, showing the position of the TATA
box, and the binding sites for GHF-1, Ets factors, the BTE, and the overlapping cAMP response element (CRE). 32P-labeled
promoter fragments (2176/174, 2176/2101, and 276/174) were obtained by PCR. The depicted Pst-1 restriction site was used
to generate the labeled fragments, 276/210 and 29/174. B, In the left panels, gel mobility shift assays were performed with 150
ng of VDR and/or RXR lacking the N-terminal A/B domain (DA/B-RXR) as fusion proteins with GST. The receptors were incubated
with the 32P-labeled proximal promoter regions indicated. For supershift assays, 1 ml of the specific antibodies against VDR or
RXR (aVDR and aRXR, respectively) was used in the binding reactions as indicated. The mobility of the receptor-containing
complexes is indicated. ns represents a nonspecific band present in the labeled 2176/174 fragment. In the right panel the same
amount of receptors was incubated with the 276/174 promoter fragment in the presence and absence of recombinant GHF-1
(GHF-1p). As indicated, 1 mM vitamin D (Vit D) or a 50-fold excess of unlabeled oligonucleotides conforming a consensus VDRE
[DR3(oli)], or the GHF-1 binding site [GHF-1(oli)], were included in the reactions.
Regulation of PRL Gene Expression by VDR 1145
 by on May 17, 2010 mend.endojournals.orgDownloaded from 
The VDRE of the PRL Gene Is Functional
To test the functionality of the VDR-binding sites of the
PRL promoter, the A and B sequences were fused to
an heterologous thymidine kinase (TK) promoter
driving the CAT reporter gene (A-PRLTKCAT and
B-PRLTKCAT). These constructs, as well as the pa-
rental TKCAT construct, were transfected into HeLa
cells together with the expression vector for VDR. The
effect of vitamin D on a TKCAT reporter gene contain-
ing a consensus DR3 response element as a positive
control was also analyzed. As shown in Fig. 6A, the
plasmid TKCAT, which does not contain a VDRE, was
unresponsive to vitamin D either in the presence or
absence of VDR. On the other hand, when VDR was
expressed, vitamin D induced A-PRLTKCAT and B-
PRLTKCAT activity by approximately 6-fold and
5-fold, respectively. A similar induction by vitamin D
(4.4-fold) was found in cells transfected with the TK-
CAT plasmid containing the consensus DR3 VDRE. As
also shown in Fig. 6A, unliganded VDR constitutively
activated the A-PRLTKCAT and B-PRLTKCAT con-
struct, but the unoccupied receptor did not stimulate
the DR3 TKCAT plasmid. These results indicate that
the B sequence must be the major element used by
VDR for both the ligand-dependent and -independent
activation of the PRL gene.
To furher test the functionality of the VDRE, this
element was mutated in the context of the 2176PRL-
CAT plasmid. Two different mutations in the B se-
quence, one affecting the 59-hemisite (2176
m1PRLCAT) and the other affecting both hemisites of
the VDRE (2176 m2PRLCAT), were transfected into
HeLa cells. Figure 6B shows that these mutations
significantly impaired the response of the PRL pro-
moter to vitamin D. Additionally, ligand-independent
stimulation by VDR was reduced by the mutations. In
contrast, the activity of these mutants was strongly
stimulated by incubation with 10 mM forskolin (data not
shown), showing that this element does not contribute
to responses elicited by other signaling pathways.
Fig. 5. Mapping of the VDRE
A, Schematic representation of the 276 to 210 fragment
showing the most proximal GHF-1 binding site and the TATA
Box. B, Synthetic oligonucleotides corresponding to the re-
gion between positions 245 to 214 designated as A, B, and
C, showing the putatives DR3-type VDREs (black arrows). C,
Gel mobility shift assay performed whit GST-VDR and GST-
RXR and the 32P-labeled A, B, and C sequences as indicated.
Fig. 6. The VDRE of the PRL Promoter Is Functional
A, The A and B sequences of the PRL promoter, as well as
a consensus DR3 element, were fused to a TKCAT construct
to give the A-PRLTKCAT, B-PRLTKCAT, and DR3-TKCAT
constructs, respectively. HeLa cells were transfected with 5
mg of these constructs or the same amount of the parental
TKCAT construct. The cells were cotransfected with 2.5 mg of
VDR expression vector, and CAT activity was determined
after 48 h of incubation in the presence or absence of 100 nM
vitamin D (vit. D). B, HeLa cells were transfected with 5 mg of
2176PRLCAT or the mutated constructs 2176 m1PRLCAT
and 2176 m2PRLCAT. These plasmids were cotransfected
with expression vectors for GHF-1 (0.4 mg) and/or VDR (2.5
mg). After 48 h, CAT activity was determined in untreated
cultures and in cultures treated with 100 nM vitamin D. Sche-
matic representations of the constructs are shown at the top.
The hemisites in the VDRE are indicated by arrows, and
mutations are shown as X.
MOL ENDO · 1999 Vol 13 No. 7
1146
 by on May 17, 2010 mend.endojournals.orgDownloaded from 
VDR Activates the PRL Gene through VDR/RXR
Heterodimers
Our results indicate that cotransfection of RXR was
not needed for the PRL response to vitamin D. Since
HeLa cells contain RXR, the endogenous receptor lev-
els appear to be sufficient to mediate the observed
response to vitamin D. To analyze whether the activa-
tion of the PRL promoter by vitamin D could be en-
hanced by overexpression of RXR, the 2176PRLCAT
construct was transfected into Hela cells in combina-
tion with the expression vectors for VDR and/or RXR in
the presence of the GHF-1 vector (Fig. 7A). The re-
sponsiveness of the PRL promoter to vitamin D was
only observed in the presence of VDR. Again, unligan-
ded VDR activated the promoter, and this effect was
increased by vitamin D. Overexpression of RXR did
not affect basal PRL promoter activity, but potentiated
both the constitutive activity of VDR and the promoter
activation by vitamin D. Similar results were obtained
in pituitary cells. Figure 7B shows that expression of
RXR in GH3 cells did not alter basal activity, but en-
hanced the response to the vitamin. Thus, it is most
likely that VDR activates the PRL promoter by het-
erodimerizing with RXR. These results are in agree-
ment with the stimulation by vitamin D through a VDRE
characterized as a DR-3 motif, since it has been pro-
posed that VDR/RXR heterodimers mediate transacti-
vation of DR-3-containing promoters (21, 22).
Transcriptional Activation by Wild-Type and
C-Terminally Truncated VDR Mutants
To evaluate the region of VDR responsible for the
ligand-dependent and ligand-independent activation,
we used two truncated mutants of VDR. In the DABC
mutant, the first 111 amino acids in the N terminus
have been eliminated. This mutant lacks both the con-
stitutive activation function AF1, and the DNA-binding
domain. The DAF2-VDR mutant lacks the last 12
amino acids in the C terminus. Thus, this mutant does
not contain the transcriptional ligand-dependent acti-
vation domain AF2. AF-2 activity appears to be due to
interaction with coactivators in a ligand-dependent
manner. Thus, the coactivator SRC-1 has been shown
to interact with the AF-2 region of VDR (23, 24). We
compared in vitro interaction of VDR and DAF2-VDR
with other coactivators [CBP and ACTR (coactivator of
thyroid hormone and retinoic acid receptors)] in gluta-
thione-S-transferase (GST) pull-down assays. As
shown in Fig. 8A in the presence of vitamin D, a
significant portion of the input of 35S-labeled VDR was
specifically retained by GST-ACTR immobilized in glu-
tathione-agarose beads, while no significant binding
was observed either in the absence of vitamin D or by
GST alone. Deletion of the 12 C-terminal amino acids
abolished binding to the coactivator, and GST-ACTR
was not retained significantly by the 35S-labeled
DAF2-VDR mutant in the presence of vitamin D. Sim-
ilar results were obtained with GST-CBP. Incubation
with vitamin D increased binding of GST-CBP to the
wild-type receptor, while binding to the DAF2-VDR
mutant was unaffected. No interaction of the GST-
CBP with 35S-luciferase used as a negative control
was detected.
Figure 8B shows the effect of cotransfection of wild-
type or mutant VDR expression plasmids on the in-
duction of 2176PRLCAT by vitamin D. Although the
DAF2-VDR binds vitamin D with a normal affinity (25),
this mutant exhibited no vitamin D-dependent activa-
tion in the presence of GHF-1. This result indicates
that the last 12 amino acids in the C terminus are
absolutely necessary for transcriptional activation in a
ligand-dependent manner and suggests that coacti-
vators that bind to the AF2 domain play an important
role in this response. In contrast, the DAF2-VDR mu-
tant was able to activate the PRL promoter in a ligand-
independent manner with at least the same potency as
the wild-type receptor. In contrast, the DABC-VDR
mutant displayed neither constitutive transcriptional
activity nor vitamin D-dependent transcriptional acti-
vation. This shows that the LBD is not sufficient for
activation and suggests that binding to the VDRE is
required.
Role of the Coactivators SRC-1 and CBP on the
Activity of the PRL Promoter
As numerous reports have emphasized the require-
ment of coactivator factors to promote full activity of
the nuclear receptors in the presence of their ligands,
Fig. 7. RXR Cooperates with VDR to Activate the PRL Pro-
moter
A, HeLa cells were transfected with 5 mg of 2176PRLCAT
and expression plasmids for GHF-1 (0.4 mg), VDR (2.5 mg),
and/or RXR (0.5 mg) as indicated. After transfection the cells
were incubated for 48 h in medium alone or with 100 nM
vitamin D (Vit. D). The results shown are the mean 6 SD of four
independent transfections. B, GH3 cells were transfected
with 5 mg of 23000PRLCAT alone or in combination with 5 mg
of RXR expression vector. CAT activity was determined after
48 h in triplicate cultures incubated in the presence and
absence of vit. D.
Regulation of PRL Gene Expression by VDR 1147
 by on May 17, 2010 mend.endojournals.orgDownloaded from 
it was of interest to analyze their role in the activation
of the PRL gene by VDR in the absence and presence
of vitamin D. For this purpose, HeLa cells were trans-
fected with the PRL promoter construct 23000PRL-
CAT, and the expression vectors for VDR, GHF-1, and
the nuclear receptor coactivators, SRC-1 and CBP
(which bind to the core AF2 region of nuclear recep-
tors). Figure 9A shows the functional effects of these
factors on PRL gene stimulation. In the absence of
GHF-1, neither protein activated the PRL promoter
(data not shown). In the presence of GHF-1, SRC-1
neither enhanced the promoter response to this pitu-
itary factor nor the constitutive activity of VDR, but
drastically potentiated the response to vitamin D.
Thus, SRC-1 serves as a good coactivator for the
stimulation of the PRL promoter by VDR in a ligand-
dependent manner. The activating effect of SRC-1 on
the PRL promoter was confirmed in pituitary GH3 cells
transfected with 23000PRLCAT. As shown in Fig. 9B,
overexpression of SRC-1 enhanced significantly the
response to vitamin D without increasing basal pro-
moter activity. Unlike SRC-1, CBP significantly en-
hanced the response to GHF-1 in HeLa cells indepen-
dently of the presence of VDR. Furthermore, CBP
potentiated not only the ligand-dependent, but also
the ligand-independent, activation mediated by VDR
(Fig. 9A). Finally, the combination of these coactivators
slightly increased the effect produced by each protein
alone. These results suggest that whereas SRC-1 acts
specifically as a nuclear receptor coactivator and in a
vitamin D-dependent manner, CBP exerts a broader
role in the regulation of the PRL gene.
Since coactivators markedly enhanced the vitamin
D-dependent activity of the wild-type VDR, it was also
of interest to analyze their role in the activity of the VDR
mutants. For this purpose, the same transfection as-
says described above in HeLa cells with wild-type
VDR, SRC-1, and CBP were also performed with the
VDR mutants (Fig. 10). Confirming the results de-
scribed above, expression of SRC-1 was unable to
activate the promoter construct in the absence of re-
ceptors, whereas CBP increased by approximately
6-fold the levels found in cells expressing GHF-1. The
Fig. 9. The Coactivators SRC-1 and CBP Potentiate the
Stimulation of the PRL Promoter by VDR
A, HeLa cells were transfected with 5 mg of 23000PRL-
CAT, 0.4 mg of GHF-1, and 2.5 mg of VDR. As indicated, 2 mg
of expression vectors for SRC-1 and CBP were also cotrans-
fected. CAT activity was determined 48 h after transfection in
cells treated in the presence or absence of 100 nM vitamin D.
B, GH3 cells were transfected with 5 mg of 23000PRLCAT
alone or in combination with 2 mg of SRC-1 expression vec-
tor. CAT activity was determined in cells treated for 48 h in the
presence and absence of vit. D. The data show the values
obtained from three independent transfections.
Fig. 8. Influence of VDR Deletion Mutants on Recruitment of Coactivators and Activation of the PRL Promoter
A, [35S]-labeled native VDR or the truncated receptor lacking the AF2 domain (DAF2) were incubated with immobilized GST or
with 0.2 mg of the fusion proteins GST-ACTR or GST-CBP in the presence and absence of 100 nM vitamin D as indicated.
[35S]-labeled luciferase was used as a negative control. The bound proteins were analyzed by SDS-PAGE and visualized by
autoradiography. The first lane in each case shows 20% of the input of the corresponding labeled protein. B, Hela cells were
cotransfected with 5 mg of the 2176PRLCAT construct and 0.4 mg of GHF-1 expression vector. The cells also received 2.5 mg
of vectors encoding the wild-type VDR, VDR-DAF2, or the truncated receptor VDR-DABC, which lacks the A/B and C domains.
After transfection the cells were incubated in medium alone or with 100 nM vitamin D (vit. D). The data represent the mean 6 SD
of three independent transfections.
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DABC-VDR mutant did not activate the PRL promoter
either constitutively or in a ligand-dependent manner
in the presence of coactivators. The DAF2-VDR mu-
tant did not confer vitamin D responsiveness to the
promoter even in the presence of coactivators. This is
not surprising, since as described before (24, 25) and
shown in Fig. 8A, the AF2 region of VDR was required
for interaction with coactivators. However, the recep-
tor lacking the AF2 region displayed a normal ligand-
independent transcriptional activity and, although this
mutant is not supposed to interact with CBP, expres-
sion of this coactivator substantially increased the
constitutive activity of DAF2-VDR. This unexpected
finding was specific for CBP, since SRC-1 did not
significantly modify ligand-independent induction by
the DAF2-VDR mutant.
Physical Interaction of VDR with GHF-1
We have previously reported that several nuclear re-
ceptors can interact with GHF-1 (26). Since the stim-
ulation of the PRL promoter by VDR requires the pres-
ence of GHF-1, we asked whether a direct protein-
protein interaction between both factors could be
involved in this functional cooperation. To address this
question, a GST-VDR fusion protein was immobilized
on glutathione-sepharose beads and used in binding
assays with in vitro translated GHF-1, labeled with
[35S]methionine. To characterize the role of vitamin D
in the interaction between these proteins, the binding
reactions were also performed in the presence of this
ligand. As shown in Fig. 11, GHF-1 interacted with
VDR, and this association was independent of the
presence of vitamin D. To map the GHF-1 domain
responsible for this interaction, different deletion mu-
tants of the protein were also used in pull-down as-
says with GST-VDR. Deletion of the homeodomain,
but not of other regions of the protein, abolished the
ability of GHF-1 to interact with VDR. This result indi-
cates that the DNA-binding domain of GHF-1 is in-
volved in binding to VDR .
DISCUSSION
It has been previously found that somatolactotroph
tumor cells respond to vitamin D with a highly selective
increase in PRL synthesis, raising the level of PRL
mRNA without affecting the level of GH mRNA (17).
We have confirmed that vitamin D increases PRL tran-
scripts in GH3 cells and have demonstrated that vita-
min D enhances PRL promoter activity in transient
transfection assays. Since pituitary-specific transcrip-
tion of the GH and PRL genes involves synergistic
interactions between GHF-1 and other promoter-bind-
ing factors, including nuclear receptors, we decided to
analyze the role of GHF-1 in the regulation of PRL gene
expression by the VDR. In this report we show that in
Fig. 10. CBP, but Not SRC-1, Potentiates the Ligand-Inde-
pendent Stimulation of the PRL Promoter by VDR
HeLa cells were transfected with 5 mg of 23000PRLCAT
and 0.4 mg of GHF-1. Additionally, 2.5 mg of expression
vector for native VDR, and the DAF2 or the DABC VDR
mutants, were cotransfected with 2 mg of vectors expressing
SRC1 and/or CBP. The cells were then incubated with or
without vitamin D for 48 h. The data show CAT activities
obtained in a representative experiment performed with du-
plicate cultures with variations of 5–15%.
Fig. 11. In Vitro Interaction of VDR with Wild-Type and Trun-
cated GHF-1 Mutants
Functional domains of GHF-1 and the internal deletion
mutants are shown in a schematic form on the left. The
hatched boxes represent the homeodomains (HB); the striped
boxes, the POU-specific domains (POU); the black boxes,
regions rich in negatively charged residues (OH); and open
boxes, remainder of protein. Thin lines denote deleted se-
quences. Mutants are named according to the deleted se-
quence. The binding activity of GHF-1 proteins with VDR was
assessed by pull-down experiments. GST-VDR (1 mg) or the
same amount of GST alone (as a negative control) immobi-
lized in glutathione-sepharose beads were incubated with 5
ml of in vitro translated GHF-1 or the truncated forms labeled
with [35S]methionine. Incubations were performed in the ab-
sence or presence of 1 mM vitamin D3. After incubation the
beads were washed, and the labeled proteins were analyzed
by SDS-PAGE and visualized by autoradiography.
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HeLa cells, VDR induces PRL gene activation both
constitutively and in a vitamin D-dependent manner
only after the expression of GHF-1.
Our data indicate that the response to vitamin D is
mediated by a sequence that binds VDR/RXR het-
erodimers and is located in the 59-flanking region of
the PRL gene between the nucleotides 245 and 227.
We have identified two putative overlapping VDREs
(starting either in nucleotide 242 or 241). The hexam-
eric core of both elements shows a high homology
with the consensus VDRE sequence RRKNSA (r 5 A or
G; K 5 G or T; S 5 C or G). As in most VDREs identified
in natural vitamin D-responsive gene promoters, the
hemisites in the PRL promoter are arranged as direct
repeats spaced by three nucleotides. As expected for
a DR3, the PRL VDRE bound VDR/RXR heterodimers
with high affinity and showed low affinity for VDR
homodimers that have been described to bind prefer-
entially to DR6-type VDREs (21, 22). It has been re-
ported that vitamin D can increase binding of VDR/
RXR to some VDREs (27) but not to others (22), and
our data show that binding to the PRL VDRE was not
affected by vitamin D. An unusual feature of this VDRE
is its close vicinity to the TATA box of the PRL gene.
Our results suggest that binding of receptor het-
erodimers to these sequences does not compete with
binding of TATA box-binding protein (TBP) to its rec-
ognition sequence, rather a synergistic action of the
receptors with the basal transcriptional machinery
could be facilitated by the close location of the VDRE.
The PRL VDRE fused to a heterologous promoter
conferred responsiveness to vitamin D, and mutation
of this element in the PRL promoter strikingly reduced
the response to vitamin D, demonstrating that this
element is functional. Most interestingly, expression of
VDR also causes a constitutive activation of the PRL
promoter, and the heterologous promoter that con-
tains the PRL VDRE was also activated upon expres-
sion of VDR. In contrast, the idealized DR3 sequence
used as a positive control only exhibits ligand-depen-
dent activation. This result suggests that the activation
by the unoccupied receptor is a specific feature of the
PRL VDRE. It has been shown that other nuclear re-
ceptors are able to activate transcription constitu-
tively, and that this activation is cell and promoter
dependent (28, 29). The molecular mechanisms un-
derlying the transcriptional effects of the unliganded
receptors are not well understood. Either there is an
interaction between VDR and cellular factors that may
be necessary for hormone-independent activity or, al-
ternatively, the receptors may inhibit the activity of
putative inhibitory factors.
The response of successive promoter truncations to
liganded or unliganded VDR shows that a PRL pro-
moter construct extending to 276 bp does not re-
spond to the actions of this receptor although it con-
tains the VDRE. The lack of the BTE and the
overlapping CRE located between 2101 and 285,
which are necessary for the activity of the PRL pro-
moter (30, 31), could be involved in the unresponsive-
ness of this promoter fragment to vitamin D. In fact,
this construct which contains one GHF-1-binding site,
does not show activation by GHF-1. However, the
presence of the BTE in the PRL promoter is not suffi-
cient to confer full responsiveness to vitamin D, since
the 2101PRLCAT construct contains this element and
only exhibits a partial response to vitamin D. Thus,
other sequences located upstream of 2101 bp appear
to contribute to the activation of the PRL promoter by
vitamin D. One of these sequences could be the RRE,
a composite element for binding of GHF-1 and Ets
factors (20). A direct protein-to-protein interaction be-
tween both factors has been recently described (18).
In most promoters the hormone response elements
are found clustered around binding sites for other
transcription factors, and the requirement for addi-
tional nonreceptor factors is consistent with the find-
ing that VDR acts with other transcription factors to
enhance gene expression synergistically (32). Se-
quences located between the nucleotides 2176 and
21597 did not further increase activation by vitamin D,
suggesting that factors binding to this region are not
involved in this response. However, the plasmid ex-
tending to 23000 bp showed in most experiments a
somewhat stronger regulation by vitamin D. This could
be due either to the presence of additional upstream
VDREs or to functional cooperation of the downstream
VDRE with other factors that bind to the upstream
sequences, as, for instance, the GHF-1-binding sites
identified in the distal enhancer. It is interesting that in
pituitary GH3 cells the activity of reporter plasmids
that do not contain the distal enhancer was extremely
low, precluding a detailed analysis of the response
element in these cells.
The critical role played by GHF-1 in the stimulatory
action of vitamin D on PRL gene expression is indi-
cated by the finding that in nonpituitary cells VDR
requires the presence of GHF-1 for the activation of
this promoter. A synergistic activation of the PRL pro-
moter by GHF-1 and other nuclear receptors has been
observed previously. Thus, the estrogen receptor is
unable to activate expression of the PRL gene unless
GHF-1 is expressed (33), and as we have recently
observed, peroxisome proliferator-activated recep-
tor-a activates the PRL promoter, and this activation is
only observed upon expression of GHF-1 (34). There
are several models to explain transcriptional syner-
gism. Synergism could reflect cooperative binding be-
tween adjacently bound factors. For instance, binding
of GHF-1 could facilitate the binding of VDR/RXR to
the promoter, resulting in greater occupancy of the
cis-acting elements, thus promoting transcription. The
fact that the most proximal GHF-1-binding site is very
close to the VDRE in the promoter could suggest the
presence of a GHF-1/VDR composite element. This
type of composite element has been described in the
distal enhancer of the GHF-1 gene for GHF-1 and the
retinoic acid receptor (RAR) and is characterized by
the cooperative binding of RAR and GHF-1. However,
we do not observe cooperative binding of GHF-1 and
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VDR/RXR heterodimers even in the presence of vita-
min D, and our gel mobility shift assays show that the
receptors and the GHF-1 bind to the promoter inde-
pendently. Therefore, we favor another model for syn-
ergism involving stabilizing interactions of receptors
and transcription factors such as GHF-1 or Ets with
multiple target sites (some of them presumably basal
transcription factors as well as coactivator proteins).
The important functional role of coactivators in the
regulation of PRL gene expression by VDR is demon-
strated by the dramatic increase in vitamin D-depen-
dent transactivation of the PRL promoter by VDR in the
presence of SRC-1 and CBP. Both proteins bind the
AF2 domain of the nuclear receptors in a ligand-de-
pendent manner (12, 24, 25, 35), and our results show
that this region is indeed involved in the recruitment of
coactivators and essential for the response to vitamin
D, which was lost in a VDR mutant that lacks the AF2
region. In contrast, this truncated receptor displayed a
constitutive activation of the PRL promoter as strong
as that of the wild-type receptor, showing that the
ligand-independent activation by VDR does not re-
quire binding of coactivators to the AF2 domain. The
finding that the AF2 mutant showed ligand-indepen-
dent activity also dismisses the possibility that the
constituve action of VDR could be secondary to acti-
vation by residual intracellular levels of vitamin D.
Although SRC-1 and CBP had a similar effect on the
vitamin D-dependent activation, a differential effect on
the vitamin D-independent action of VDR was also
observed. Thus, whereas VDR constitutive activity
was essentially unaffected by SRC-1, CBP signifi-
cantly increased the effect of unoccupied VDR. Fur-
thermore, the vitamin D-independent activation elic-
ited by the AF2 VDR mutant was also potentiated by
CBP. The latter effect was totally unexpected, since
this mutant lacks the CBP-interacting region (12). This
suggests that CBP might exert this action indirectly by
binding to other factor/s that, in turn, associate with
VDR. The best candidate for this interaction is again
GHF-1. CBP significantly potentiates the stimulatory
effect of GHF-1 on the promoter. On the other hand,
we have recently observed a direct protein-to-protein
interaction between GHF-1 and CBP (34). This inter-
action maps to the POU domain of GHF-1 (36) and to
the region of CBP contained between amino acids
1–1099 and 1679–1858, the same domains of interac-
tion with other transcription factors including Ets (37).
We have also previously reported a direct associa-
tion of GHF-1 with several nuclear receptors (26). This
finding, as well as the important role of GHF-1 in the
activation of the PRL gene by VDR, suggested that this
receptor could also interact with GHF-1. Our results
demonstrate that indeed this association exists, and
that VDR interacts in a ligand-independent manner
with the homeodomain (the DNA-binding domain)
of GHF-1. Thus, although the interaction might re-
cruit VDR and GHF-1 to the promoter, binding of
VDR/GHF-1 heterodimers to the promoter was not
observed.
As a whole, our data suggest that the simultaneous
binding of VDR/RXR and GHF-1 to their close cognate
sites in the promoter, as well as the direct interactions
with other transcription factors, coactivators, and
components of the basal transcription machinery, could
facilitate promoter occupancy and govern transcrip-
tional activation of the PRL promoter synergistically.
MATERIALS and METHODS
RNA Extraction and Hybridization
GH3 cells were cultured in RPMI medium containing 15%
horse serum and 2.5% FCS. For the experiments the cells
were incubated for 24 h in a medium containing a hormone-
stripped serum by treatment with resin AG1x8 and activated
charcoal. The cells were then treated for 48 h with 100 nM
vitamin D. Total RNA was extracted from the cell cultures with
guanidine thiocyanate. The RNA was run in 1% formalde-
hyde-agarose gels and transferred to nylon-nitrocellulose
membranes (Nytran, Schleicher & Schuell, Dassel, Germany)
for Northern blot analysis. The RNA was stained with 0.02%
methylene blue. The blots were hybridized with a cDNA probe
for rat PRL labeled by nick translation. Hybridizations were at
42 C with 50% formamide, and the more stringent wash was
at 42 C with 13 SSC-0.1% SDS.
Plasmids
The constructs 23000PRLCAT and 2176PRLCAT were gen-
erated from plasmids containing the 59-flanking region of the
rat PRL promoter (from 23000 to 174, and from 2176 to
174 bp, respectively) in a pBL-CAT2 vector in which the
thymidine kinase promoter had been deleted (38). Since the
pBLCAT vector contains an AP-1 like sequence at 134/139,
which could mask some promoter responses (19), a 301-bp
fragment containing this element was deleted by digestion
with AatII and NarI. The constructs were then blunt-ended
and religated. 21597PRLCAT was obtained by removing a
XbaI/NsiI fragment of 1403 bp from 23000PRLCAT and then
blunt-ended and religated. The 2423PRLCAT plasmid was
obtained by digestion of 23000PRLCAT with HindIII and
religation. 2101 and 276PRLCAT have been previosly de-
scribed (7). The mutated constructs 2176 m1PRLCAT and
2176 m2PRLCAT were obtained by PCR. In the first PCR the
sense oligonucleotides 59-CATGAAGCCGTCGAAGTTTA-39
(for M1), and 59-CATGAAGCCGTCGAAGCCTTATAAA-
GTC-39 (for M2) containing the desired nucleotide changes,
as well as the antisense oligonucleotide 59-GACTCGAGTC-
GACATCGATGCCATTGGGATATATC-39, were used to gen-
erate mutated fragments. After an elongation phase, a sec-
ond PCR was performed using these fragments. The sense
oligonucleotide for this reaction was 59-cccaagcttTGGC-
CACTATGTCTTCCT-39 containing a HindIII site and as anti-
sense 59-GACTCGAGTCGACAT-39. The mutated sequences
were cut with HindIII and XhoI and subcloned in pBLCAT3.
The mutations were confirmed by sequencing. The A oligo-
nucleotide, 59-agctTGAAGGTGTCGAAGGTTTATAAAGTC-
AATGTCg-39, which contains the sequences 245 to 214 of
the rat PRL promoter, was cloned into HindIII/BamHI sites of
pBL-CAT2 (without the AP-1 like sequence) upstream of the
TK promoter to construct A-PRLTKCAT. The B oligonucleo-
tide containing the promoter sequences from 245 to 227,
59-agctTGAAGGTGTCGAAGGTTTA-39, was also cloned into
the HindIII site of pBL-CAT 2 upstream of the TK promoter
and then blunt ended and religated to produce B-PRLTKCAT.
The plasmid DR3-TKCAT, which contains the DR3 consen-
sus oligonucleotide 59-agctcAGGTCAAGGAGGTCAg-39, has
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been previously described (39). The expression vectors for
rat GHF-1 (40), human RXRa (41), human VDR (42), human
CBP (43), and human SRC-1 (44) have been described pre-
viously. The expression vector for the DAF2-VDR mutant
was constructed by PCR using the human VDR expression
plasmid as a template and the oligonucleotides 59-GGAGC-
AGCAGCGCATCATT-39 and 59-CGCGGATCCTCACGTTAG-
CTTCATGCTGC-39 to generate a 872-bp fragment. This frag-
ment was digested with BstXI and BamHI and cloned into the
pSG5 expression vector. This receptor lacks the last 12
C-terminal amino acids, which contain the AF2 region. For
the DABC-VDR mutant, the oligonucleotides 59-GGAATTC-
CATGGAGGAGGAGGCCTTG-39 and 59-CGGGATCCTCAG-
GAGATC TCATTGCC-39 were used to generate a 972-bp
fragment and were then digested with EcoRI and BamHI and
subcloned into pSG5. This construct generates a truncated
receptor lacking 149 N-terminal amino acids that include the
A/B region and the DNA-binding domain (C region). pGST-
VDR, which expresses a fusion protein between glutathione
S-transferase (GST) and VDR, was obtained by PCR using
the pSG5-VDR plasmid as a template and the oligonucleo-
tides 59-CGGGATCCATGGAGGCAATGGCGG-39 and 59-
GGAATTCTCAGGAGATCTCAT TGC-39 to generate the VDR
cDNA (1031 bp). This fragment was then subcloned into
BamHI/EcoRI sites of the pGEX-2T plasmid. pGST-DA/BRXR
plasmid (lacking the A/B domain), was also constructed
by PCR but using the pSG5-hRXR and the oligonucleo-
tides 59-GGAATTCTGATGGGCCTCAATGGCGTCC-39 and
59GCTCTA GACTAAGTCATTTGGTGCGG-39 to generate a
1078-bp fragment that was subcloned into EcoRI/HindIII
sites of the pGEX-2T plasmid. The constructs GST-ACTR and
GST-CBP, which express the cDNAs coding for the amino
acids 621–821 and 1–1099 of ACTR and CBP, respectively,
have been previously described (45, 46). These fragments
contain the nuclear receptor-interacting sequences of both
proteins.
Cell Culture and Transfections
HeLa cells were cultured in DMEM containig 10% FCS and
were transfected by calcium phosphate with the reporter CAT
constructs. GH3 cells were shifted to DMEM and transfected
with calcium phosphate with a glycerol shock. In cotransfec-
tion experiments the reporter plasmids were transfected with
2.5 mg of VDR and/or 0.5 mg of RXR, in the presence or
absence of 0.4 mg of GHF-1 expression vectors. When indi-
cated, 2 mg of vectors encoding SRC-1 or CBP were also
used in cotransfection experiments. In all cases the total
amount of DNA among different transfections was kept con-
stant by addition of empty noncoding expression vectors.
Each transfection also received 0.5 mg of a luciferase vector
as a control for transfection efficiency. CAT activity was de-
termined by incubation of the cell extracts with [14C]chlor-
amphenicol. The unreacted and acetylated [14C]chloram-
phenicol was separated by TLC and quantified with an
InstantImager (Packard Instrument Co., Camberra). The data
are expressed as the percentage of acetylated forms after
each treatment. Each experiment was repeated at least three
times with similar results.
Protein Preparations
GHF-1 and its truncated forms cloned in Bluescript SK- (36),
were used for in vitro transcription and translation following
the manufacturer’s recommendations of the TNTT7 Quick
coupled transcription/translation System (Promega Corp.,
Madison, WI). The reactions were translated in the presence
of 40 mCi of [35S]methionine (Amersham Pharmacia Biotech,
Arlington Heights, IL). Five microliters of the reaction product
were resolved in 10% SDS-PAGE. The gel was dried and
autoradiographed overnight. Recombinant purified GHF-1
was a generous gift from Dr. Castrillo. The GST-fusion pro-
teins, VDR, DABRXR, CBP, and ACTR, were expressed in the
bacterial strain BL21 (DE3). They were grown at 37 C in 23
YT [Tryptone, 16 g/liter yeast extract; NaCl, 5 g/liter (pH 7)]
until the absorbance reached 0.6. Then the induction was
performed at 30 C for 2 h with 0.4 mM isopropyl b-D-thioga-
lactopyranoside and were purified following the recommen-
dations of Pharmacia Biotech, (Piscataway, NJ).
Mobility Shift Assays
Gel retardation assays were performed with the recombinant
GST-fusion proteins. Oligonucleotides corresponding to the
A, B, and C fragments of the PRL promoter were used as
probes. A and B oligonucleotides have been described
above, and C oligonucleotide, 59-agctCGAAGGTTTATA-
AAGTCAATGTCg-39, contains the 236 to 214 promoter se-
quence. For the binding reaction, the proteins were incu-
bated on ice for 15 min in a buffer [20 mM Tris HCL (pH 7.5),
75 mM KCl, 1 mM dithiothreitol, 5 mg/ml BSA, 13% glycerol]
containing 3 mg poly (dI-dC) and then for 15–20 min at room
temperature with approximately 50,000 cpm of labeled dou-
ble-stranded oligonucleotide end labeled with [32P]CTP, us-
ing Klenow fragment as kinase. In addition, the labeled frag-
ment 2176 to 174 was obtained by PCR using the
oligonucleotides 59-cccaagcttTGGCCACTATGTCTTCCT-39
and 59-AACAGCCAAGTGTCAGCC-39 as primers. The region
2176 to 1101 was obtained with the antisense oligonucle-
otide 59-CAATCATCTATTTCCGTCAT-39. For the PCRs the
first oligonucleotide was previously end labeled with [32P]ATP
using T4-polynucleotide kinase. Similarly, the 2101 to 1 74
and 276 to 174 fragments were made by PCR with the 59
oligonucleotides 59-ATGACGGAAATAGATGATTG-39 and 59-
GGAAGAGGATGCCTGAT-39, respectively (end labeled pre-
viously with [32P]ATP). For competition experiments an ex-
cess of unlabeled doubled-stranded oligonucleotides were
added to the binding reactions: as a DR-3 type we used
59-agctcAGGTCAAGGAGGTCAg-39 and for the GHF-1 bind-
ing site we used 59-CCAGCCATGAATAAATGTATAGGG-39.
For supershift experiments, specific antibodies against VDR
(aVDR) and RXR (aRXR) were added to the binding reactions
before the addition of the labeled fragment. Finally, DNA-
protein complexes were resolved on 6% polyacrylamide gels
in 0.53 TBE buffer. The gels were then dried and autoradio-
graphed at 270 C.
Protein-Protein Interactions
Pull-down assays were performed with 5 ml of in vitro trans-
lated L-[35S]methionine-labeled GHF-1, VDR, or the same
amount of their truncated forms. These proteins were incu-
bated with the fusion proteins GST-VDR, GST-ACTR, or
GST-CBP or with the same amount of GST as a control,
immobilized in glutathione-sepharose beads as previously
described (34, 35). Where indicated, vitamin D was included
in the binding reaction. The bound proteins were analyzed by
SDS-PAGE and autoradiography.
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2000 Annual Conference of the International Embryo Transfer Society
January 8–11, 2000
The MECC, Maastricht, The Netherlands
General Information: Free communication will be presented as posters, abstracts of which will
be published in the January 2000 issue of Theriogenology. The first author or a representative
is required to present an expanded report of the data in poster format at the Annual Conference.
Students may enter their abstract in a competition sponsored by the IETS Foundation and are
also eligible to compete for three US$500 travel awards. The IETS Foundation also offers a
Young Scientists International Travel Award of up to US$1500 for travel and lodging. Details on
eligibility, judging procedures, and prizes are included with the instruction packet.
Abstract Requirements: Abstracts must be in English and prepared strictly according to the
instructions for submission. The language should be concise and avoid jargon. Abbreviations
must be defined and should be used sparingly. Abstracts should consist of unpublished, original
data that contains objectives, experimental methods (including statistical methods), results, and
conclusions. The Program Chairman and two other referees will subject each abstract to
rigorous scientific review. Rejection by the Program Chairman is final. If withdrawal of an
abstract becomes necessary, notify the Program Chairman by October 1, 1999.
Submission Restrictions: Due to space restrictions, submissions are limited. An individual may
not be first author of more than one abstract and his or her name may not appear on more than
four abstracts.
Submission Deadlines: Abstracts must be submitted via the web site or by a hard copy only. No
FAX copies will be accepted. The firm deadline for receipt of the abstract via the web site is August
18, 1999 by midnight CST. Abstracts received after this date will be rejected. The Program
Chairman strongly encourages all authors to use the new electronic submission format in order to
reduce costs associated with paper submission. Authors without Internet access can submit a paper
copy of their abstract. The abstract must follow the given format and should be mailed to be
received no later than August 16, 1999. Abstracts received after this date will be rejected without
exception.
Author Agreements: Authors need to be aware of patent considerations and copyright con-
siderations before submitting an abstract for publication. By submitting an abstract, the author
concedes (1) that the information in the submitted manuscript has never been published and is
the work of the named authors, who all agree to be listed as co-authors, and (2) that the first
author or a representative will present an expanded report of the data in poster form at the
annual conference and that the work reported has not been published elsewhere. Failure to
present a poster after your abstract has been published in the conference proceedings can
result in rejection of abstacts submitted by your laboratory in future years.
Instructions for preparation of abstracts as well as information about the IETS Foundation
Student Competition and Travel Awards may be obtained by contacting:
Fran Gardner, Executive Secretary
IETS Headquarters
1111 North Dunlap Avenue
Savoy, IL 61874 USA
Phone: (217) 356-3182, FAX: (217) 398-4119, E-mail: iets@assochq.org
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